Edwards (EW) Gains From Balanced Core Growth and New Launches
https://www.zacks.com/stock/news/2226830/edwards-ew-gains-from-balanced-core-growth-and-new-launches?cid=CS-ZC-FT-analyst_blog|zer_report_update-2226830
Feb 15, 2024 - Edwards (EW) is demonstrating the strong performance of the SAPIEN 3 Ultra valve in the United States, Europe and Rest of World.
0
ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 Device
https://www.zacks.com/stock/news/2225610/resmed-rmd-to-treat-sleep-apnea-with-new-aircurve-11-device?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2225610
Feb 13, 2024 - ResMed's (RMD) new AirCurve11 series incorporates myAir and AirView digital health apps to provide maximum comfort and support during therapy.
0
Globus Medical (GMED) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
https://www.zacks.com/stock/news/2225550/globus-medical-gmed-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2225550
Feb 13, 2024 - Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Integer (ITGR) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
https://www.zacks.com/stock/news/2224651/integer-itgr-q4-earnings-on-the-horizon-analysts-insights-on-key-performance-measures?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2224651
Feb 12, 2024 - Beyond analysts' top -and-bottom-line estimates for Integer (ITGR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
0
Fresenius Medical (FMS) Gets FDA Nod for New Hemodialysis System
https://www.zacks.com/stock/news/2224203/fresenius-medical-fms-gets-fda-nod-for-new-hemodialysis-system?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2224203
Feb 09, 2024 - Fresenius Medical (FMS) receives an FDA nod for its new 5008X Hemodialysis System that aims to provide better dialysis therapy for kidney patients in the United States.
0
Here's Why You Should Invest in Boston Scientific (BSX) Now
https://www.zacks.com/stock/news/2223513/here-s-why-you-should-invest-in-boston-scientific-bsx-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2223513
Feb 08, 2024 - Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.
0
Integer (ITGR) Reports Next Week: Wall Street Expects Earnings Growth
https://www.zacks.com/stock/news/2223427/integer-itgr-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2223427
Feb 08, 2024 - Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Microbot Medical (MBOT) Files IDE to Start Human Clinical Study
https://www.zacks.com/stock/news/2222672/microbot-medical-mbot-files-ide-to-start-human-clinical-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2222672
Feb 07, 2024 - Microbot Medical (MBOT) files an IDE with the FDA, approval of which will enable the company to proceed with its human clinical study in the United States.
0
ITGR or EW: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2221192/itgr-or-ew-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2221192
Feb 05, 2024 - ITGR vs. EW: Which Stock Is the Better Value Option?
0
InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS
https://www.zacks.com/stock/news/2221179/inspiremd-s-nspr-ce-mark-recertification-to-boost-cguard-eps?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2221179
Feb 05, 2024 - InspireMD's (NSPR) CE Mark Recertification under MDR is likely to help the company boost the CGuard EPS for carotid artery revascularization care along with advancing with new products.
0